INCY Incyte
- 51.680
- +0.500+0.98%
- 52.320
- +0.640+1.24%
Incyte News
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates From VRTX
Express News | Incyte : Oppenheimer Cuts Target Price to $84 From $92
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84
Truist Financial Keeps Their Buy Rating on Incyte (INCY)
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
Express News | Incyte Corp : Oppenheimer Cuts Target Price to $84 From $93
Incyte's Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns
Incyte (INCY) Gets a Buy From Piper Sandler
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million.Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled rec
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Across the recent three months, 10 analysts have shared their insights on Incyte (NASDAQ:INCY), expressing a variety of opinions spanning from bullish to bearish.The table below provides a concise ove
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte To Buy Privately Held Escient Pharma
Incyte Initiated at Neutral by Cantor Fitzgerald
Incyte Initiated at Neutral by Cantor Fitzgerald
Express News | Cantor Fitzgerald Initiates Coverage On Incyte With Neutral Rating
Analysis
Price Target
No Data
